



Effective Date:
Monday, May 01, 2023

Test Updates

Modified
Test 3245U was removed

In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled important changes regarding a number of tests we perform. Listed below are the types of changes that may be included in this notification, effective Monday, May 01, 2023

Test Changes - Tests that have had changes to the method/ CPT code, units of measurement, scope of analysis, reference comments, or specimen requirements.

Discontinued Tests - Tests being discontinued with alternate testing suggestions.

Please use this information to update your computer systems/records. These changes are important to ensure standardization of our mutual laboratory databases.

If you have any questions about the information contained in this notification, please call our Client Support Department at (866) 522-2206. Thank you for your continued support of NMS Labs and your assistance in implementing these changes.

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. NMS Labs does not assume responsibility for billing errors due to reliance on the CPT Codes listed in this document.



Effective Date:
Monday, May 01, 2023

Test Updates

Test	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
1809B	Doxapram, Blood								•
1809SP	Doxapram, Serum/Plasma								•
2055SP	Ethylene Glycol Overexposure Profile, Serum/Plasma			•	•				
2345B	Hydroflumethiazide, Blood								•
2345SP	Hydroflumethiazide, Serum/Plasma								•
2529U	Lithium Proficiency, Urine		•	•					
2520B	Lithium, Blood		•						
2520FL	Lithium, Fluid		•	•					
2520R	Lithium, RBCs		•					•	
2520SP	Lithium, Serum/Plasma		•						
2520U	Lithium, Urine		•	•					
3250SP	Oxalate, Serum/Plasma			•	•				
3427SP	Perfluoroalkyl Substances (PFAS), Serum/Plasma			•	•	•			
3426SP	Perfluorooctanoic Acid, Serum/Plasma								•
3772B	Pindolol, Blood								•
3772SP	Pindolol, Serum/Plasma								•
4395B	Ticlopidine, Blood								•
4395SP	Ticlopidine, Serum/Plasma								•
5691B	Verapamil Confirmation (Qualitative), Blood								•
9322B	Verapamil Screen, Blood								•



Test Updates

Test Changes

2055SP Ethylene Glycol Overexposure Profile, Serum/Plasma

Summary of Changes: Specimen Requirements (Transport Temperature) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.

Specimen Requirements: 5 mL Serum or Plasma

Transport Temperature: Refrigerated

Specimen Container: Plastic container (preservative-free)

Light Protection: Not Required

Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Green top tube (Sodium Heparin)
Promptly centrifuge with refrigeration and separate Serum or Plasma into chilled plastic screw capped vial using approved guidelines. Freeze immediately and ship with dry ice.

Ascorbic acid at very high concentration (exceeding 51 mcmmol/mL plasma) can interfere. It is recommended that patients refrain from taking excessive amounts of vitamin C or vitamin C rich food for at least 48 hours prior to collection.

Rejection Criteria: Received Room Temperature. Gray top tube (Sodium Fluoride / Potassium Oxalate). Polymer gel separation tube (SST or PST).

Stability: Room Temperature: Not Stable

Refrigerated: 14 day(s)

Frozen (-20 °C): 3 month(s)

2529U Lithium Proficiency, Urine

Summary of Changes: Specimen Requirements were changed.
Methods/CPT Codes were changed [ICP/MS (None)]

Specimen Requirements: 1 mL Urine

Transport Temperature: Refrigerated

Specimen Container: Plastic container (Acid washed or Trace metal-free)

Light Protection: Not Required

Special Handling: Avoid exposure to gadolinium-based contrast media for 48 hours prior to sample collection.

Rejection Criteria: None

Scope of Analysis: ICP/MS (None): Lithium

Method (CPT Code)

2520B Lithium, Blood

Summary of Changes: Methods/CPT Codes were changed [ICP/MS (80178)]

Scope of Analysis: ICP/MS (80178): Lithium

Method (CPT Code)

2520FL Lithium, Fluid



Test Updates

Test Changes

Summary of Changes: Specimen Requirements were changed.
Methods/CPT Codes were changed [ICP/MS (80178)]

Specimen Requirements: 4 mL Fluid
Transport Temperature: Refrigerated
Specimen Container: Plastic container (Acid washed or Trace metal-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Scope of Analysis: ICP/MS (80178): Lithium
Method (CPT Code)

2520R Lithium, RBCs

Summary of Changes: Reference Comment was changed.
Methods/CPT Codes were changed [ICP/MS (80178)]

Scope of Analysis: ICP/MS (80178): Lithium
Method (CPT Code)

Analyte Name	Units	Reference Comment
Lithium	mEq/L	Generally: 0.02-0.80 mEq/L. The RBC sample used for analysis was measured by weight and multiplied by the density of human RBC (1.10 g/mL) to obtain mEq/L units.

2520SP Lithium, Serum/Plasma

Summary of Changes: Methods/CPT Codes were changed [ICP/MS (80178)]

Scope of Analysis: ICP/MS (80178): Lithium
Method (CPT Code)

2520U Lithium, Urine

Summary of Changes: Specimen Requirements were changed.
Methods/CPT Codes were changed [ICP/MS (80178)]

Specimen Requirements: 1 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (Acid washed or Trace metal-free)
Light Protection: Not Required
Special Handling: Avoid exposure to gadolinium-based contrast media for 48 hours prior to sample collection.
Rejection Criteria: None



Test Updates

Test Changes

Scope of Analysis: ICP/MS (80178): Lithium
Method (CPT Code)

3250SP Oxalate, Serum/Plasma

Summary of Changes: Specimen Requirements (Transport Temperature) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.

Specimen Requirements: 2 mL Serum or Plasma

Transport Temperature: Refrigerated

Specimen Container: Plastic container (preservative-free)

Light Protection: Not Required

Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Green top tube (Sodium Heparin)
Promptly centrifuge with refrigeration and separate Serum or Plasma into chilled plastic screw capped vial using approved guidelines. Freeze immediately and ship with dry ice.

Ascorbic acid at very high concentration (exceeding 51 mcmmol/mL plasma) can interfere. It is recommended that patients refrain from taking excessive amounts of vitamin C or vitamin C rich food for at least 48 hours prior to collection.

Rejection Criteria: Received Room Temperature. Gray top tube (Sodium Fluoride / Potassium Oxalate). Polymer gel separation tube (SST or PST).

Stability: Room Temperature: Not Stable

Refrigerated: 14 day(s)

Frozen (-20 °C): 3 month(s)

3427SP Perfluoroalkyl Substances (PFAS), Serum/Plasma

Summary of Changes: Specimen Requirements were changed.
Stability was changed.
Scope of Analysis was changed.
PFBS, PFHpA, Branched PFOA Isomers, Linear PFOA Isomer, Total PFOA Isomers, PFHxS, PFNA, Branched PFOS Isomers, Linear PFOS Isomer and Total PFOS Isomers were added.
Perfluorobutanesulfonic Acid (as the linear isomer), Perfluoroheptanoic Acid (as the linear isomer), Perfluorooctanoic Acid (as the linear isomer), Perfluorohexanesulfonic Acid (as the linear isomer), Perfluorononanoic Acid (as the linear isomer) and Perfluorooctanesulfonic Acid (as the linear isomer) were removed.



Test Updates

Test Changes

- Specimen Requirements: 1 mL Serum or Plasma
 Transport Temperature: Refrigerated
 Specimen Container: Plastic container (preservative-free)
 Light Protection: Not Required
 Special Handling: Sample collection devices coated with PTFE/Teflon® and PVDF should be avoided because of potential specimen contamination.
 Serum: Collect sample in Red top tube
 Plasma: Collect sample in Lavender top tube (EDTA).
 Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
 Rejection Criteria: Polymer gel separation tube (SST or PST).
 Stability: Room Temperature: 17 day(s)
 Refrigerated: 17 day(s)
 Frozen (-20 °C): 3 month(s)
 Scope of Analysis: LC-MS/MS (83921): PFBS, PFHpA, Branched PFOA Isomers, Linear PFOA Isomer,
 Method (CPT Code) Total PFOA Isomers, PFHxS, PFNA, Branched PFOS Isomers, Linear PFOS Isomer, Total PFOS Isomers

Analyte Name	Units	Reference Comment
PFBS	ng/mL	General U.S. population from CDC-NHANES (2013-2014) (n=2168) is typically below 0.10 ng/mL (95th percentile)
PFHpA	ng/mL	General U.S. population from CDC-NHANES (2013-2014) (n=2168) is typically below 0.20 ng/mL (95% CI, 0.10-0.20 ng/mL) (95th percentile)
Branched PFOA Isomers	ng/mL	General U.S. population from CDC-NHANES (2017-2018) (n=1929) is typically below 0.20 ng/mL (95% CI, <0.10-0.20 ng/mL) (95th percentile)
Linear PFOA Isomer	ng/mL	General U.S. population from CDC-NHANES (2017-2018) (n=1929) is typically below 3.7 ng/mL (95% CI, 3.1-5.0 ng/mL) (95th percentile)
Total PFOA Isomers	ng/mL	General U.S. population from CDC-NHANES (2017-2018) (n=1929) is typically below 3.77 ng/mL (95% CI, 3.17-5.07 ng/mL) (95th percentile)
PFHxS	ng/mL	General U.S. population from CDC-NHANES (2017-2018) (n=1929) is typically below 3.7 ng/mL (95% CI, 3.3-5.6 ng/mL) (95th percentile)
PFNA	ng/mL	General U.S. population from CDC-NHANES (2017-2018) (n=1929) is typically below 1.4 ng/mL (95% CI, 1.1-1.8 ng/mL) (95th percentile)



Effective Date:
Monday, May 01, 2023

Test Updates

Test Changes

Analyte Name	Units	Reference Comment
Branched PFOS Isomers	ng/mL	General U.S. population from CDC-NHANES (2017-2018) (n=1929) is typically below 4.5 ng/mL (95% CI, 3.8-5.4 ng/mL) (95th percentile)
Linear PFOS Isomer	ng/mL	General U.S. population from CDC-NHANES (2017-2018) (n=1929) is typically below 10.4 ng/mL (95% CI, 9.4-12.0 ng/mL) (95th percentile)
Total PFOS Isomers	ng/mL	General U.S. population from CDC-NHANES (2017-2018) (n=1929) is typically below 14.6 ng/mL (95% CI, 13.1-16.5 ng/mL) (95th percentile)



Effective Date:
Monday, May 01, 2023

Test Updates

Discontinued Tests

Test	Test Name	Alternative Test
1809B	Doxapram, Blood	No Alternate Tests Available
1809SP	Doxapram, Serum/Plasma	No Alternate Tests Available
2345B	Hydroflumethiazide, Blood	No Alternate Tests Available
2345SP	Hydroflumethiazide, Serum/Plasma	No Alternate Tests Available
3426SP	Perfluorooctanoic Acid, Serum/Plasma	3428SP - PFASure TM, Serum/Plasma
3772B	Pindolol, Blood	No Alternate Tests Available
3772SP	Pindolol, Serum/Plasma	No Alternate Tests Available
4395B	Ticlopidine, Blood	No Alternate Tests Available
4395SP	Ticlopidine, Serum/Plasma	No Alternate Tests Available
5691B	Verapamil Confirmation (Qualitative), Blood	No Alternate Tests Available
9322B	Verapamil Screen, Blood	4770B - Verapamil, Blood